← Leaderboards
Michael D Kappelman
Univ Of North Carolina Chapel Hill
$4,091,448
Attributed
$7,430,911
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$5,666,595 · 2
NIH$1,764,316 · 3
By mechanism
U01$5,666,595 · 2
U19$1,307,118 · 2
K08$457,198 · 1
Top collaborators
- Andres Hurtado-Lorenzo5 shared
- Meenakshi Bewtra3 shared
- Siddharth Singh3 shared
- James D Lewis1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Ronald I Swanstrom$43,560,887
- Joseph J. Eron$450,672,292
- Robert S Sandler$41,787,492
- Michael G Hudgens$22,139,032
- Bryan J. Weiner$11,631,061
Others in their field
Top investigators on “Inflammatory Bowel Diseases”
- Judy H Cho · University Of Chicago$48,459,647
- Ramnik J Xavier · Broad Institute, Inc.$43,517,622
- Mark J Daly · Broad Institute, Inc.$37,682,914
- Richard S Blumberg · Children'S Hospital Boston$36,446,455
- Stacey Gabriel · Massachusetts Institute Of Technology$34,637,180
- Eugene B Chang · University Of Chicago$28,912,342
Research focus
Inflammatory Bowel DiseasesChildhoodBaseChildRegistriesSamplingS DiseaseGastroenterologistPhysiciansMeasurementAffectChronicResearch InfrastructureResearch PersonnelComplexDesignCohort StudiesCrohn&AposFundingFutureEnsureLifeQuality Of LifeUlcerative Colitis
Grant awards (13)
RFA-DP-23-002, Improving Outcomes and Reducing Disparities for Patients with Inflammatory Bowel Disease through Epidemiology, Enhanced Disease Management, Dissemination, and Education$774,997
U01 · FY2025 · DP · contact PI
RFA-DP-23-002, Improving Outcomes and Reducing Disparities for Patients with Inflammatory Bowel Disease through Epidemiology, Enhanced Disease Management, Dissemination, and Education$774,997
U01 · FY2024 · DP · contact PI
RFA-DP-23-002, Improving Outcomes and Reducing Disparities for Patients with Inflammatory Bowel Disease through Epidemiology, Enhanced Disease Management, Dissemination, and Education$700,000
U01 · FY2023 · DP · contact PI
Diversity within the Incidence, Prevalence, Treatment and Outcomes of Patients with IBD$414,033
U01 · FY2022 · DP
Diversity within the Incidence, Prevalence, Treatment and Outcomes of Patients with IBD$714,121
U01 · FY2021 · DP
Diversity within the Incidence, Prevalence, Treatment and Outcomes of Patients with IBD$714,447
U01 · FY2020 · DP
Diversity within the Incidence, Prevalence, Treatment and Outcomes of Patients with IBD$787,000
U01 · FY2019 · DP
Diversity within the Incidence, Prevalence, Treatment and Outcomes of Patients with IBD$787,000
U01 · FY2018 · DP
Clinical Validation of PROMIS Measures in a Pediatric Crohns Disease Clinical Trial$753,128
U19 · FY2015 · AR · contact PI
Enhancing Meaningfulness and Usefulness of Pediatric and Caregiver PROMIS Measures Across Illness Groups$553,990
U19 · FY2015 · AR · contact PI
Exposure to antibiotics during infancy and subsequent risk of Crohn's disease: a$151,707
K08 · FY2013 · DK · contact PI
Exposure to antibiotics during infancy and subsequent risk of Crohn's disease: a$151,887
K08 · FY2012 · DK · contact PI
Exposure to antibiotics during infancy and subsequent risk of Crohn's disease: a$153,604
K08 · FY2011 · DK · contact PI